SITC Archive Library

SITC 30th Anniversary Annual Meeting (2015): Mechanisms and Responses to Immune Therapy
November 6-8, 2015 
Gaylord National Hotel & Convention Center National Harbor, MD

Co-Chairs:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer A. Wargo, MD, MMSc  – University of Texas MD Anderson Cancer Center

SITC 30th Anniversary Annual Meeting Organizers 
Sandra Demaria, MD – Weill Cornell Medical College 
Madhav Dhodapkar, MD – Yale University 
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre 
Jennifer A. Wargo, MD – University of Texas MD Anderson Cancer Center
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute

Program Summary
Major advances in cancer therapy have been made in the past several years through the use of immunotherapy, however limitations still exist. To address these limitations, there are ongoing efforts to better understand mechanisms of response and resistance to these forms of treatment. This session focused on these efforts, and highlighted contributions of both host and tumor-related factors to responses to immunotherapy. Topics covered included use of host genomic and immune data to predict and modulate responses to therapy, as well as host and tumor-specific contributions to responses in animal models as well as in longitudinal samples from patients on therapy. Specific insights into how to improve responses to therapy were also discussed.

About the SITC 30th Anniversary Annual Meeting 
SITC's 30th Anniversary Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy research. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for both structured and informal discussions including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as ongoing SITC projects. 

Target Audience
The target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment. 

#Biomarkers #Melanoma #Video #AnnualMeeting #SITC 
#ImmuneCheckpointInhibitors #Ipilimumab #AlliedHealth #Clinician #Oncologist #Pharmacist 
#Researcher #2015